Previous 10 | Next 10 |
2023-08-29 02:38:56 ET Summary Merit Medical Systems stock has been repriced to the downside following its last two acquisitions and flat Q2 numbers. Q2 FY'23 saw growth in sales and gross margin, driven by the cardiovascular and peripheral intervention segments. MMSI's acquis...
2023-08-15 16:37:13 ET More on AngioDynamics AngioDynamics, Inc. ( ANGO ) Q4 2023 Earnings Call Transcript AngioDynamics, Inc. 2023 Q4 - Results - Earnings Call Presentation A Win-Win Scenario From The AngioDynamics And Merit Medical Deal AngioDynamics: A...
Pivotal Milestone Accelerates Pathway to Specific Indication AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality o...
Pivotal Study of NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and ...
2023-07-25 09:53:00 ET Achieving success as a growth investor revolves around picking companies that are taking new and potentially winning approaches to solving existing problems. These businesses can take their place as disruptors in a particular market, which can fuel growth in revenue a...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced the appointment of Lorinda Burg...
2023-07-12 11:13:07 ET AngioDynamics, Inc. (ANGO) Q4 2023 Earnings Conference Call July 12, 2023, 08:00 AM ET Company Participants Jim Clemmer - President and Chief Executive Officer Steve Trowbridge - Executive Vice President and Chief Financial Officer Confer...
2023-07-12 07:01:29 ET AngioDynamics press release ( NASDAQ: ANGO ): Q4 Non-GAAP EPS of $0.02 in-line. Revenue of $91.1M (+4.7% Y/Y) beats by $0.66M . Med Tech net sales of $26.5 million increased 17.2% Med Device net sales of $64.6 million increased 0.3% T...
Fiscal Year 2023 Fourth Quarter Highlights Net sales of $91.1 million increased 4.7% compared to the prior-year quarter Med Tech net sales of $26.5 million increased 17.2% Med Device net sales of $64.6 million increased 0.3% Gross margin of 50.9% declined 2...
News, Short Squeeze, Breakout and More Instantly...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.92 for Q2 2024 Bank of America Corporation (BAC) is expected to report $0.79 for Q2 2024 Aehr Test Systems (AEHR) is expected to report $0.09 for Q4 2024 America Movil S.A.B. de C.V.n Depositary Shares (each representing t...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourt...
AZZ Inc. (AZZ) is expected to report $1.31 for Q1 2025 Express Inc. (EXPRQ) is expected to report for Q1 2025 Aeon Co. Ltd. ADR (AONNY) is expected to report for Q1 2025 Altamira Therapeutics Ltd. (CYTO) is expected to report for Q1 2024 Bassett Furniture Industries Incorporated (...